PHARMACOECONOMIC ANALYSIS OF THE USE OF OXALIPLATIN CHEMOTHERAPY FOR COLORECTAL CANCER.REAL (ACTUAL) CLINICAL PRACTICE DATA

Abstract

to assess the effectiveness of medicines the retrospective observational study of 1343 case of hospitalization (case reports) of 214 colorectal cancer patients treated with oxaliplatin at the St. Petersburg State Health Care Institution «City Clinical Oncology Dispensary» in 2008-2010 was done. Pharmacoeconomic analysis of application of oxaliplatin in colorectal cancer was performed. Cost-effectiveness analysis was used. Calculation of direct medical costs, direct non-medical costs and indirect costs was performed. Three trade names of oxaliplatin was used: eloxatin – 42.2%; platikad – 31.6%; eksorum – 26.2%. Middle cover price of case reportwas 252,294 rubles. In average oxaliplatin therapy was effective in 83.1%. ICER for eloxatin was 8,801 and 18,162 compared to eksorum and platikad respectively. As a result it was shown that the treatment with eloxatin was clinical and cost-effective.

Keywords

• colorectal cancer
• pharmacoeconomic
• «real world» data